---
title: "Feasibility Study of IV Remdesivir for Long COVID: ERASE LC Trial Results"
id: "medrxiv-3-an-open-label-feasibility-study-of-remdesivir-in-long-covid-results-from-the"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-an-open-label-feasibility-study-of-remdesivir-in-long-covid-results-from-the"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1?rss=1"
published_at: "2026-07-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Feasibility Study of IV Remdesivir for Long COVID: ERASE LC Trial Results
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-an-open-label-feasibility-study-of-remdesivir-in-long-covid-results-from-the
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1?rss=1)
- **Published At:** 2026-07-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The ERASE LC trial assessed feasibility of a five-day intravenous **remdesivir** course in adults with a confirmed diagnosis of **Long COVID** (LC) across two UK sites. Recruitment, treatment completion, acceptability, and safety were primary feasibility outcomes. - Of 106 individuals screened, 73 participants were enrolled; 71 (97%) completed the 5-day IV remdesivir regimen, and 70 (96%) completed follow-up assessments. High completion rates were reported for clinical tests, patient-reported outcomes, and symptom tracking. - No severe adverse reactions were reported during the study, indicating an acceptable short-term safety profile in this small open-label cohort. - Exploratory outcomes included patient-reported measures such as the Fatigue Assessment Scale (FAS) and clinical measures including the 6-minute walk test (6MWT); improvements were observed in several exploratory endpoints, though specific effect sizes and statistical details were not reported in the abstract. - The authors conclude that administering IV remdesivir in people with LC is feasible and acceptable; however, they emphasise that rigorous evaluation in large-scale randomized controlled trials is required to determine true efficacy and clinical utility. - Trial registration is listed as NCT05911906. Ethical approvals were obtained from the UK Health Research Authority Research Ethics Committee (24/SC/0118), the Administration of Radioactive Substances Advisory Committee (AA-8765), and the Medicines and Healthcare products Regulatory Agency (24/SC/0118). - The study was supported by Gilead Sciences. Data from the study are available from the authors upon reasonable request. The report is a preprint and has not been peer reviewed; authors caution it should not guide clinical practice.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=ZDF46U1gEC8ww1I9tf48QclPj1lhX_tP3C11a4gnP.Y-1785298079.5042927-1.2.1.1-dvi_anOrpUmHj2dJAiiouWXbRyfowaJYg7QQqoi4EKg) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial [ View ORCID Profile](http://orcid.org/0000-0002-8163-7032)Mark A Faghy, [ View ORCID Profile](http://orcid.org/0000-0002-2516-5923)Jade Chynoweth, [ View ORCID Profile](http://orcid.org/0000-0001-7867-8469)Anton Barnett, [ View ORCID Profile](http://orcid.org/0009-0002-7308-0163)Lindsay Skipper, [ View ORCID Profile](http://orcid.org/0000-0002-5228-2623)Victoria Allgar, [ View ORCID Profile](http://orcid.org/0000-0002-8288-0261)Helen Neilens, [ View ORCID Profile](http://orcid.org/0000-0002-1060-0427)Kayle-Anne Sands, [ View ORCID Profile](http://orcid.org/0000-0002-6886-7001)Amber Lord, [ View ORCID Profile](http://orcid.org/0009-0000-9618-6417)Helen Hambly, [ View ORCID Profile](http://orcid.org/0009-0009-5476-9134)Paigan Aspinall, Chris Rollinson, [ View ORCID Profile](http://orcid.org/0000-0002-6826-418X)William Strain, [ View ORCID Profile](http://orcid.org/0000-0002-7510-2103)Rebecca Owen, [ View ORCID Profile](http://orcid.org/0000-0001-8608-8231)Callum Thomas, [ View ORCID Profile](http://orcid.org/0000-0001-6816-5600)Marie Grigg, [ View ORCID Profile](http://orcid.org/0000-0002-8355-5508)Sascha Kranen, [ View ORCID Profile](http://orcid.org/0000-0002-3896-2542)Kinan Mokbel, [ View ORCID Profile](http://orcid.org/0000-0002-8266-0381)Hairil Razak, [ View ORCID Profile](http://orcid.org/0000-0001-6282-0352)Ruth Ashton, [ View ORCID Profile](http://orcid.org/0000-0003-4152-9704)Ian Maidment, Tom Bewick doi: https://doi.org/10.64898/2026.07.26.26358852 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Mark A Faghy 1 Loughborough University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mark%2BA%2BFaghy%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Faghy%20MA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMark%2BA%2BFaghy%2B) * [ORCID record for Mark A Faghy](http://orcid.org/0000-0002-8163-7032 "Open in new tab") * For correspondence: m.a.faghy@lboro.ac.uk Jade Chynoweth 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jade%2BChynoweth%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chynoweth%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJade%2BChynoweth%2B) * [ORCID record for Jade Chynoweth](http://orcid.org/0000-0002-2516-5923 "Open in new tab") Anton Barnett 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anton%2BBarnett%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Barnett%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnton%2BBarnett%2B) * [ORCID record for Anton Barnett](http://orcid.org/0000-0001-7867-8469 "Open in new tab") Lindsay Skipper 3 University of Derby; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lindsay%2BSkipper%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Skipper%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALindsay%2BSkipper%2B) * [ORCID record for Lindsay Skipper](http://orcid.org/0009-0002-7308-0163 "Open in new tab") Victoria Allgar 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Victoria%2BAllgar%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Allgar%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVictoria%2BAllgar%2B) * [ORCID record for Victoria Allgar](http://orcid.org/0000-0002-5228-2623 "Open in new tab") Helen Neilens 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Helen%2BNeilens%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Neilens%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHelen%2BNeilens%2B) * [ORCID record for Helen Neilens](http://orcid.org/0000-0002-8288-0261 "Open in new tab") Kayle-Anne Sands 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kayle-Anne%2BSands%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sands%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKayle-Anne%2BSands%2B) * [ORCID record for Kayle-Anne Sands](http://orcid.org/0000-0002-1060-0427 "Open in new tab") Amber Lord 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amber%2BLord%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lord%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmber%2BLord%2B) * [ORCID record for Amber Lord](http://orcid.org/0000-0002-6886-7001 "Open in new tab") Helen Hambly 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Helen%2BHambly%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hambly%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHelen%2BHambly%2B) * [ORCID record for Helen Hambly](http://orcid.org/0009-0000-9618-6417 "Open in new tab") Paigan Aspinall 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paigan%2BAspinall%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aspinall%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaigan%2BAspinall%2B) * [ORCID record for Paigan Aspinall](http://orcid.org/0009-0009-5476-9134 "Open in new tab") Chris Rollinson 2 Pen CTU; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chris%2BRollinson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rollinson%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChris%2BRollinson%2B) William Strain 4 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=William%2BStrain%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Strain%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilliam%2BStrain%2B) * [ORCID record for William Strain](http://orcid.org/0000-0002-6826-418X "Open in new tab") Rebecca Owen 3 University of Derby; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rebecca%2BOwen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Owen%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARebecca%2BOwen%2B) * [ORCID record for Rebecca Owen](http://orcid.org/0000-0002-7510-2103 "Open in new tab") Callum Thomas 3 University of Derby; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Callum%2BThomas%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Thomas%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACallum%2BThomas%2B) * [ORCID record for Callum Thomas](http://orcid.org/0000-0001-8608-8231 "Open in new tab") Marie Grigg 3 University of Derby; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marie%2BGrigg%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Grigg%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarie%2BGrigg%2B) * [ORCID record for Marie Grigg](http://orcid.org/0000-0001-6816-5600 "Open in new tab") Sascha Kranen 4 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sascha%2BKranen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kranen%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASascha%2BKranen%2B) * [ORCID record for Sascha Kranen](http://orcid.org/0000-0002-8355-5508 "Open in new tab") Kinan Mokbel 4 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kinan%2BMokbel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mokbel%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKinan%2BMokbel%2B) * [ORCID record for Kinan Mokbel](http://orcid.org/0000-0002-3896-2542 "Open in new tab") Hairil Razak 4 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hairil%2BRazak%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Razak%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHairil%2BRazak%2B) * [ORCID record for Hairil Razak](http://orcid.org/0000-0002-8266-0381 "Open in new tab") Ruth Ashton 5 Coventry University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ruth%2BAshton%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ashton%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARuth%2BAshton%2B) * [ORCID record for Ruth Ashton](http://orcid.org/0000-0001-6282-0352 "Open in new tab") Ian Maidment 6 Aston University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ian%2BMaidment%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Maidment%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIan%2BMaidment%2B) * [ORCID record for Ian Maidment](http://orcid.org/0000-0003-4152-9704 "Open in new tab") Tom Bewick 7 University Hospitals of Derby and Burton NHS Foundation Trust * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tom%2BBewick%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bewick%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATom%2BBewick%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1266773/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1266773/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1266773/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1266773/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1266773/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the feasibility of a five‑day IV remdesivir intervention for individuals with LC. Methods: Seventy-three participants aged ≥18 years with a confirmed LC diagnosis were recruited across two sites in the United Kingdom to receive a five‑day course of IV remdesivir. Primary feasibility outcomes included recruitment, treatment completion, acceptability, and safety. Exploratory patient-reported (e.g. Fatigue Assessment Scale [FAS]) and clinical outcomes (e.g. 6-minute walk test [6MWT]) were also collected. Results: Of 106 individuals screened, 73 were enrolled and 71 (97%) completed the 5-day IV remdesivir regimen. Follow-up assessments were completed by 70 participants (96%), with high completion rates observed across clinical assessments, patient-reported outcomes and symptom tracking. No severe adverse reactions were reported. Improvements were also observed in several exploratory patient-reported and clinical outcomes. Conclusion: We demonstrated the feasibility and acceptability of administering IV remdesivir in people with LC. Analysis of secondary outcomes suggests therapeutic promise, but rigorous evaluation in large-scale randomised controlled trials is essential to determine the true efficacy and clinical utility of intravenous remdesivir in this population. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT05911906 ### Clinical Protocols ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics approval was obtained from the UK Health Research Authority Research Ethics Committee (24/SC/0118), the Administration of Radioactive Substances Advisory Committee (AA-8765), and the Medicines and Healthcare products Regulatory Agency (24/SC/0118). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. ## Funder Information Declared Gilead Sciences (United States), #IN-UK-540-6640 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.07.26.26358852v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.07.26.26350307v1 "Deep Learning-Based Pretreatment Cardiovascular Risk Stratification in Women with Breast Cancer")[Next ](https://www.medrxiv.org/content/10.64898/2026.07.27.26359007v1 "Can non-routine data collection help decision-making for gambiense sleeping sickness? Using active adaptive management to assess the potential of vector control") Posted July 28, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64
## Related Clinical Research

- [Ebola Preparedness: Addressing the Gap in Virus Species Research](https://medichelpline.com/clinical-feed/stat-news-9-opinion-we-prepared-for-ebola-but-not-this-ebola.md)
- [Bundibugyo Ebola outbreak reveals gaps in Ebola preparedness and need for pan-filovirus tools](https://medichelpline.com/clinical-feed/stat-news-1-opinion-we-prepared-for-ebola-but-not-this-ebola.md)
- [Phase 1 trials and PARTNERS platform target Bundibugyo Ebola strain](https://medichelpline.com/clinical-feed/medical-news-today-40-phase-1-trials-for-ebola-treatments-and-vaccines-offer-hope-say-experts.md)
- [Virologic findings from REDPINE: remdesivir activity and resistance in renally impaired and immuno](https://medichelpline.com/clinical-feed/pubmed-42429789.md) (DOI: 10.1128/aac.01912-25)
- [Bundibugyo virus infection treated with MBP134 monoclonal antibodies and remdesivir: a case report](https://medichelpline.com/clinical-feed/nature-0-a-case-of-bundibugyo-virus-disease-treated-with-monoclonal-antibodies-and.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.